Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Clinial Trials

- PMLiVE

AZ expects return to growth this year after 2017 decline

Soriot says the pharma company is 'turning a corner'

- PMLiVE

EMA set to review Teva’s migraine injection

Fremanezumab could be approved for prophylactic use of migraines

- PMLiVE

World Cancer Day and the role of people-centred care

How people-centred is current cancer care? To support #WorldCancerDay, we explore this question, and look at the ways we can individually and collectively reduce the burden of cancer.

Porterhouse Medical Group

- PMLiVE

Alexion appoints new senior VP for EMEAC region

Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland

- PMLiVE

Pfizer’s Alan Maine moves to Edelman

He joins the communications firm as its senior director

- PMLiVE

Porterhouse speakers to focus on skills, data sharing and transparency at 17th TIPPA Meeting

Strategies to Improve Operations and Compliance in Medical Communications

Porterhouse Medical Group

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

- PMLiVE

WE Communications wins BenevolentAI account

It will be tasked with raising the artificial intelligence firm's profile

- PMLiVE

Dr Sotirios Stergiopoulos leaves Shire for Ipsen

He becomes the French biopharma’s chief medical officer

- PMLiVE

Merck appoints new chief information officer

Dirk Toepfer joins the group from Metro Systems, where he was head of IT

Large-scale NHS commissioning models require new partnership approach from pharma

Steve How, Paul Midgley and Sue Thomas, of Wilmington Healthcare, explore how pharma should respond to the NHS’s move towards more collaborative, joined up working

Wilmington Healthcare

Roche Basel Switzerland

Roche’s autism drug scores FDA breakthrough status

Balovaptan could become the first drug to treat autism spectrum disorder

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links